Tashiro Manabu, Sakurada Yumiko, Iwabuchi Kentaro, Mochizuki Hideki, Kato Motohisa, Aoki Mariko, Funaki Yoshihito, Itoh Masatoshi, Iwata Ren, Wong Dean F, Yanai Kazuhiko
Department of Pharmacology, Tohoku University School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
J Clin Pharmacol. 2004 Aug;44(8):890-900. doi: 10.1177/0091270004267590.
Histamine H1-receptor (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders. This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of histamine H1-receptor occupancy (H1RO) in the brain. Subjective sleepiness and psychomotor performance were measured in 20 healthy Japanese volunteers at baseline and 90 min after administration of fexofenadine 120 mg or cetirizine 20 mg in a double-blind, placebo-controlled crossover study. Hydroxyzine 30 mg was included as a positive control. H1RO was measured using positron emission tomography (PET) with (11)C-doxepin in 12 of the 20 subjects, and a further 11 volunteers were recruited to act as controls. In psychomotor tests, fexofenadine was not significantly different from placebo and significantly less impairing than cetirizine on some tasks, as well as significantly less impairing than hydroxyzine on all tasks. For subjective sleepiness, fexofenadine was not significantly different from placebo, whereas cetirizine showed a trend toward increased sleepiness compared with fexofenadine and placebo. H1RO was negligible with fexofenadine (-0.1%) but moderately high with cetirizine (26.0%). In conclusion, fexofenadine 120 mg is distinguishable from cetirizine 20 mg, as assessed by H1RO and psychomotor testing.
组胺H1受体(H1R)拮抗剂,即抗组胺药,在用于治疗过敏性疾病时常常会引起镇静副作用。本研究使用3种不同标准比较了第二代抗组胺药非索非那定和西替利嗪的镇静情况:通过斯坦福嗜睡量表评估主观嗜睡程度、进行客观精神运动测试(简单和选择反应时间测试以及在4种不同暴露时长下的视觉辨别测试),以及测量大脑中的组胺H1受体占有率(H1RO)。在一项双盲、安慰剂对照的交叉研究中,对20名健康日本志愿者在基线时以及服用120 mg非索非那定或20 mg西替利嗪90分钟后测量主观嗜睡程度和精神运动表现。将30 mg羟嗪作为阳性对照。在20名受试者中的12名中使用正电子发射断层扫描(PET)结合(11)C-多塞平测量H1RO,并另外招募11名志愿者作为对照。在精神运动测试中,非索非那定与安慰剂无显著差异,并且在某些任务上比西替利嗪的损害显著更小,在所有任务上比羟嗪的损害也显著更小。对于主观嗜睡程度,非索非那定与安慰剂无显著差异,而西替利嗪与非索非那定和安慰剂相比有嗜睡增加的趋势。非索非那定的H1RO可忽略不计(-0.1%),而西替利嗪的H1RO则处于中等较高水平(26.0%)。总之,通过H1RO和精神运动测试评估,120 mg非索非那定与20 mg西替利嗪有所不同。